The efficacies of plasma exchange and IVIg for GBS treatment were first established in the 1980s and 1990s [4,5], but subsequent clinical trials have failed to demonstrate beneficial effects of alternative therapeutic approaches such as interferon-β1a [21], brain-derived neurotrophic factor [22], and mycophenolate mofetil [22]. Here, BDNF is linked to Guillain-Barre syndrome.